Yes ccb, your excellent overview of m2m now brings up the question of what percentage of m2ms progress to the primary endpoint criteria (5? 10? 20?) because that will affect trial outcome. Do you know? I would imagine most have at least some symptom(s)or they would not be m2m. And I understand you’re already looking into what percentage get better on their own. As others have stated besides me answers to these questions will give more insight into what we can expect from the trials.